iX Biopharma Ltd.

Catalist:42C Stock Report

Market Cap: S$22.1m

iX Biopharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Eddy Lee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure17yrs
CEO ownership24.8%
Management average tenure4yrs
Board average tenure6.9yrs

Recent management updates

Recent updates

CEO

Eddy Lee (70 yo)

17yrs

Tenure

Mr. Yip Hang Lee, also known as Eddy, serves as the Chief Executive Officer of iX Biopharma Ltd. and has been its Executive Chairman since January 17, 2008. Mr. Lee is responsible for running the affairs o...

Leadership Team

NamePositionTenureCompensationOwnership
Chin Beng Lim
Chief Pharmacist4yrsno datano data
Yip Hang Lee
Executive Chairman & CEOno datano data24.83%
SGD 5.5m
Sien Lup Chew
Chief Financial Officer8.8yrsno datano data
Janakan Krishnarajah
COO & Chief Medical Officer5.8yrsno data0.69%
SGD 152.3k
Iain Cook
Chief Scientist9.3yrsno datano data
Eva Tan
Chief Commercial Officer4yrsno datano data
Kuan Loong Lai
Secretary2.9yrsno datano data
Soo Fern Lee
Secretary2.9yrsno datano data

4.0yrs

Average Tenure

64yo

Average Age

Experienced Management: 42C's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yip Hang Lee
Executive Chairman & CEO17yrsno data24.83%
SGD 5.5m
Patrick Donald Davies
Non-Executive Lead Independent Director5.1yrsno datano data
Shing Tung Ho
Non-Executive Non-Independent Director11.8yrsno data1.26%
SGD 278.4k
Bob Rappaport
Member of Scientific Advisory Board8.8yrsno datano data
Stephan A. Schug
Member of Scientific Advisory Boardno datano datano data
Yandi Liu
Member of Scientific Advisory Board4yrsno datano data
Woon Keng Teo
Independent Non-Executive Director2.2yrsno datano data

6.9yrs

Average Tenure

57yo

Average Age

Experienced Board: 42C's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:14
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

iX Biopharma Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Lee Keng LingDBS Bank Ltd
Paul ChewPhillip Securities Pte Ltd
Wee Kuang TayPhillip Securities Pte Ltd